Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model
Background Amino acid metabolism is essential for tumor cell proliferation and regulation of immune cell function. However, the clinical significance of free amino acids (plasma-free amino acids (PFAAs)) and tryptophan-related metabolites in plasma has not been fully understood in patients with non-...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/5/e004420.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542912759463936 |
|---|---|
| author | Akihiko Kawahara Tetsuro Sasada Koichi Azuma Hidenobu Ishii Norikazu Matsuo Takaaki Tokito Tomoaki Hoshino Yohei Miyagi Huihui Xiang Tomoyuki Tagami Rika Kasajima Yumiko Kato Sachise Karakawa Shinya Kikuchi Akira Imaizumi Kenta Murotani |
| author_facet | Akihiko Kawahara Tetsuro Sasada Koichi Azuma Hidenobu Ishii Norikazu Matsuo Takaaki Tokito Tomoaki Hoshino Yohei Miyagi Huihui Xiang Tomoyuki Tagami Rika Kasajima Yumiko Kato Sachise Karakawa Shinya Kikuchi Akira Imaizumi Kenta Murotani |
| author_sort | Akihiko Kawahara |
| collection | DOAJ |
| description | Background Amino acid metabolism is essential for tumor cell proliferation and regulation of immune cell function. However, the clinical significance of free amino acids (plasma-free amino acids (PFAAs)) and tryptophan-related metabolites in plasma has not been fully understood in patients with non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors.Methods We conducted a single cohort observational study. Peripheral blood samples were collected from 53 patients with NSCLC before treatment with PD-1 (Programmed cell death-1) inhibitors. The plasma concentrations of 21 PFAAs, 14 metabolites, and neopterin were measured by liquid chromatography–mass spectrometry. Using Cox hazard analysis with these variables, a multivariate model was established to stratify patient overall survival (OS). Gene expression in peripheral blood mononuclear cells (PBMCs) was compared between the high-risk and low-risk patients by this multivariate model.Results On Cox proportional hazard analysis, higher concentrations of seven PFAAs (glycine, histidine, threonine, alanine, citrulline, arginine, and tryptophan) as well as lower concentrations of three metabolites (3h-kynurenine, anthranilic acid, and quinolinic acid) and neopterin in plasma were significantly correlated with better OS (p<0.05). In particular, the multivariate model, composed of a combination of serine, glycine, arginine, and quinolinic acid, could most efficiently stratify patient OS (concordance index=0.775, HR=3.23, 95% CI 2.04 to 5.26). From the transcriptome analysis in PBMCs, this multivariate model was significantly correlated with the gene signatures related to immune responses, such as CD8 T-cell activation/proliferation and proinflammatory immune responses, and 12 amino acid-related genes were differentially expressed between the high-risk and low-risk groups.Conclusions The multivariate model with PFAAs and metabolites in plasma might be useful for stratifying patients who will benefit from PD-1 inhibitors. |
| format | Article |
| id | doaj-art-b3cd71445f81409abe70043d29a38ab9 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2022-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-b3cd71445f81409abe70043d29a38ab92025-02-03T12:30:14ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-05-0110510.1136/jitc-2021-004420Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate modelAkihiko Kawahara0Tetsuro Sasada1Koichi Azuma2Hidenobu Ishii3Norikazu Matsuo4Takaaki Tokito5Tomoaki Hoshino6Yohei Miyagi7Huihui Xiang8Tomoyuki Tagami9Rika Kasajima10Yumiko Kato11Sachise Karakawa12Shinya Kikuchi13Akira Imaizumi14Kenta Murotani15Department of Diagnostic Pathology, Kurume University Hospital, Kurume, JapanDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, JapanDepartment of Internal Medicine, Kurume University School of Medicine, Kurume, JapanDivision of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, JapanDepartment of Internal Medicine, Kurume University School of Medicine, Kurume, JapanDepartment of Internal Medicine, Kurume University School of Medicine, Kurume, JapanDivision of Respirology, Neurology, and Rheumatology Department of Internal Medicine, Kurume University School of Medicine, Kurume, JapanKanagawa Cancer Center Research Institute, Yokohama, JapanMolecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, JapanResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co Inc, Kawasaki, JapanMolecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, JapanResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co Inc, Kawasaki, JapanResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co Inc, Kawasaki, JapanResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co Inc, Kawasaki, JapanResearch Institute for Bioscience Products and Fine Chemicals, Ajinomoto Co Inc, Kawasaki, JapanBiostatistics Center, Kurume University School of Medicine, Kurume, JapanBackground Amino acid metabolism is essential for tumor cell proliferation and regulation of immune cell function. However, the clinical significance of free amino acids (plasma-free amino acids (PFAAs)) and tryptophan-related metabolites in plasma has not been fully understood in patients with non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors.Methods We conducted a single cohort observational study. Peripheral blood samples were collected from 53 patients with NSCLC before treatment with PD-1 (Programmed cell death-1) inhibitors. The plasma concentrations of 21 PFAAs, 14 metabolites, and neopterin were measured by liquid chromatography–mass spectrometry. Using Cox hazard analysis with these variables, a multivariate model was established to stratify patient overall survival (OS). Gene expression in peripheral blood mononuclear cells (PBMCs) was compared between the high-risk and low-risk patients by this multivariate model.Results On Cox proportional hazard analysis, higher concentrations of seven PFAAs (glycine, histidine, threonine, alanine, citrulline, arginine, and tryptophan) as well as lower concentrations of three metabolites (3h-kynurenine, anthranilic acid, and quinolinic acid) and neopterin in plasma were significantly correlated with better OS (p<0.05). In particular, the multivariate model, composed of a combination of serine, glycine, arginine, and quinolinic acid, could most efficiently stratify patient OS (concordance index=0.775, HR=3.23, 95% CI 2.04 to 5.26). From the transcriptome analysis in PBMCs, this multivariate model was significantly correlated with the gene signatures related to immune responses, such as CD8 T-cell activation/proliferation and proinflammatory immune responses, and 12 amino acid-related genes were differentially expressed between the high-risk and low-risk groups.Conclusions The multivariate model with PFAAs and metabolites in plasma might be useful for stratifying patients who will benefit from PD-1 inhibitors.https://jitc.bmj.com/content/10/5/e004420.full |
| spellingShingle | Akihiko Kawahara Tetsuro Sasada Koichi Azuma Hidenobu Ishii Norikazu Matsuo Takaaki Tokito Tomoaki Hoshino Yohei Miyagi Huihui Xiang Tomoyuki Tagami Rika Kasajima Yumiko Kato Sachise Karakawa Shinya Kikuchi Akira Imaizumi Kenta Murotani Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model Journal for ImmunoTherapy of Cancer |
| title | Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model |
| title_full | Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model |
| title_fullStr | Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model |
| title_full_unstemmed | Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model |
| title_short | Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model |
| title_sort | clinical significance of plasma free amino acids and tryptophan metabolites in patients with non small cell lung cancer receiving pd 1 inhibitor a pilot cohort study for developing a prognostic multivariate model |
| url | https://jitc.bmj.com/content/10/5/e004420.full |
| work_keys_str_mv | AT akihikokawahara clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT tetsurosasada clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT koichiazuma clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT hidenobuishii clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT norikazumatsuo clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT takaakitokito clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT tomoakihoshino clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT yoheimiyagi clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT huihuixiang clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT tomoyukitagami clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT rikakasajima clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT yumikokato clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT sachisekarakawa clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT shinyakikuchi clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT akiraimaizumi clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel AT kentamurotani clinicalsignificanceofplasmafreeaminoacidsandtryptophanmetabolitesinpatientswithnonsmallcelllungcancerreceivingpd1inhibitorapilotcohortstudyfordevelopingaprognosticmultivariatemodel |